Screener
CG Oncology CGON EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from CG Oncology’s reported figures.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's EBITDA?
- CG Oncology (CGON) reported EBITDA of -$85.55M in Q2 2026.
- How has CG Oncology's EBITDA changed year-over-year?
- CG Oncology's EBITDA decreased by 76.1% year-over-year, from -$48.59M to -$85.55M.
- What is the long-term trend for CG Oncology's EBITDA?
- Over 2 years (2023 to 2025), CG Oncology's EBITDA has grown at a 84.8% compound annual growth rate (CAGR), from -$55.43M to -$189.33M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about CG Oncology's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude